A pharma giant is moving past one patent cliff, but the next is already looming. The tape cares less about the victory lap and more about the revenue bridge: pipeline, pricing, and timing before the n

What happened: Novartis reported disappointing data, highlighting its challenge to build its next generation of blockbuster medicines after a series of clinical trial setbacks. Why it matters: The company is moving past one patent cliff, but another is already looming, and the trial setbacks weigh on efforts to build future blockbuster medicines.

Novartis reported disappointing data, highlighting its challenge to build its next generation of blockbuster medicines after a series of clinical trial setbacks.

The company is moving past one patent cliff, but another is already looming, and the trial setbacks weigh on efforts to build future blockbuster medicines.